Placebo

Compared with a placebo injection, platelet-rich plasma injections yielded similar outcomes at 1 year for patients with greater trochanteric pain syndrome caused by either bursitis or gluteal tendinopathy, according to published results.

WASHINGTON — Rising rates of ACR20 response in the placebo arms of rheumatoid arthritis trials may be related to increasingly globalized recruitment patterns, according to data presented at ACR Convergence 2024.

Placebos administered without deception, or nondeceptive placebos, may offer an alternative and effective way to help people manage prolonged stress, according to a study published in Applied Psychology: Health and Well-Being.

Sobi and Apellis Pharmaceuticals Inc. announced results from the phase 3 Valiant study showing the drug pegcetacoplan reduced proteinuria and stabilized eGFR compared to placebo in patients with glomerulopathy or glomerulonephritis.

The FDA has granted accelerated approval for Fabhalta to treat proteinuria in patients with primary IgA nephropathy, according to a press release.

According to published results, krill oil supplementation did not improve VAS pain scores for patients with significant knee osteoarthritis pain and effusion-synovitis compared with placebo treatment.

LONG BEACH, Calif. — Iptacopan may be superior to placebo in reducing proteinuria at 9 months, with early onset and effect consistency, according to data presented at the National Kidney Foundation Spring Clinical Meetings, here.

In this Healio video exclusive, Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, discussed the top items from the February issue, including an exploration of how the placebo effect can be applied in rheumatology.

I am thrilled to introduce our cover story this month, “‘Exploring the Power of Their Mind’: Data May Offer Clues to Harnessing the Placebo Effect,” to the readers of Healio Rheumatology. I say this for several reasons.

Titrated low-dose amitriptyline demonstrated effectiveness and tolerability as a second-line therapy for irritable bowel syndrome in primary care compared with placebo, a randomized study in the United Kingdom showed.